Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.66 EUR | +0.52% | +3.90% | -14.90% |
Business Summary
The United States account for 70.1% of net sales.
Number of employees: 34,100
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 46,159 | 100.0 % | 45,006 | 100.0 % | -2.50% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
70.1
%
| 31,828 | 69.0 % | 31,555 | 70.1 % | -0.86% |
International
28.3
%
| 13,497 | 29.2 % | 12,752 | 28.3 % | -5.52% |
Other
1.6
%
| 834 | 1.8 % | 699 | 1.6 % | -16.19% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 53 | 15-01-31 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | 02-12-31 | |
Chief Tech/Sci/R&D Officer | - | - | |
Samit Hirawat
CTO | Chief Tech/Sci/R&D Officer | 55 | 18-12-31 |
Robert Plenge
CTO | Chief Tech/Sci/R&D Officer | 53 | 19-10-31 |
Laura Hortas
IRO | Public Communications Contact | - | - |
Corporate Officer/Principal | - | - | |
Cari Gallman
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 19-11-19 |
Peter Arduini
BRD | Director/Board Member | 59 | 16-03-31 |
Derica Rice
BRD | Director/Board Member | 59 | 20-08-31 |
Paula Price
BRD | Director/Board Member | 62 | 20-08-31 |
Theodore Samuels
BRD | Director/Board Member | 69 | 17-02-20 |
David Elkins
DFI | Director of Finance/CFO | 55 | 19-11-19 |
Chief Executive Officer | 53 | 15-01-31 | |
Julia Haller
BRD | Director/Board Member | 69 | 19-11-19 |
Karen Vousden
BRD | Director/Board Member | 66 | 17-12-31 |
Director/Board Member | 56 | 21-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 2,923,100,096 | 2,024,918,592 ( 69.27 %) | 896,000,000 ( 30.65 %) | 69.27 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
5,075,304 | 5.31% | 136,322,665 $ | |
759,145 | 6.36% | 19,358,198 $ | |
COMPUGEN LTD. 5.31% | 4,757,058 | 5.31% | 10,322,816 $ |
CELULARITY INC. 5.49% | 1,195,327 | 5.49% | 3,717,467 $ |
Company contact information
Bristol Myers Squibb Co.
Route 206 & Province Line Road
08543, Princeton
+609 252 4621
http://www.bms.comGroup companies
Name | Category and Sector |
---|---|
Bristol-Myers Squibb India Pvt Ltd.
Bristol-Myers Squibb India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb India Pvt Ltd. is an Indian company that discovers, develops, and delivers medicines for immuno-oncology. The company is based in Mumbai, India. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb SA (Spain)
| |
Bristol-Myers Squibb AE
| |
Swords Laboratories Unlimited Co.
Swords Laboratories Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Swords Laboratories Unlimited Co. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Swords, Ireland. |
Pharmaceuticals: Major
|
BMS Strategic Portfolio Investments Holdings, Inc.
| |
Bristol-Myers Squibb (Finland) Oy Ab
Bristol-Myers Squibb (Finland) Oy Ab Pharmaceuticals: GenericHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb (Finland) Oy Ab is a Finnish pharmaceutical manufacturing company. The company is based in Vantaa, Finland. The company was founded in 1974. Simone Böhrer has been the CEO of the company since 2020. |
Pharmaceuticals: Generic
|
Celgene Alpine Investment Co. LLC
| |
Bristol-Myers Squibb SARL
Bristol-Myers Squibb SARL Medical DistributorsDistribution Services Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France. |
Medical Distributors
|
Celgene Alpine Investment Co. III LLC
Celgene Alpine Investment Co. III LLC Financial ConglomeratesFinance Part of Bristol Myers Squibb Co., Celgene Alpine Investment Co. III LLC is an American company that provides investment services. The company is located in the US. |
Financial Conglomerates
|
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.61% | 815B | |
+44.25% | 654B | |
-6.33% | 354B | |
+20.62% | 337B | |
+10.44% | 302B | |
+18.45% | 247B | |
+2.09% | 229B | |
+13.03% | 219B | |
+8.61% | 171B |
- Stock Market
- Equities
- BMY Stock
- BRM Stock
- Company Bristol-Myers Squibb Company